PMID- 31558180
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20210217
IS  - 1555-3906 (Electronic)
IS  - 0965-0407 (Print)
IS  - 0965-0407 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Feb 7
TI  - Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by 
      CalliSpheres((R)) in 275 Hepatocellular Carcinoma Patients: Results From the 
      Chinese CalliSpheres((R)) Transarterial Chemoembolization in Liver Cancer (CTILC) 
      Study.
PG  - 75-94
LID - 10.3727/096504019X15662966719585 [doi]
AB  - The purpose of this study was to investigate the efficacy and safety of 
      drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in 
      Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for 
      treatment response as well as survival. A total of 275 HCC patients were included 
      in this prospective study. Treatment response was assessed by modified Response 
      Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival 
      (PFS) as well as overall survival (OS) were determined. Liver function and 
      adverse events (AEs) were assessed before and after DEB-TACE operation. Complete 
      response (CR), partial response (PR), and objective response rate (ORR) were 
      22.9%, 60.7%, and 83.6%, respectively. The mean PFS was 362 (95% CI: 34.9-375) 
      days, the 6-month PFS rate was 89.4 +/- 2.1%, while the mean OS was 380 (95% CI: 
      370-389) days, and the 6-month OS rate was 94.4 +/- 1.7%. Multivariate logistic 
      regression revealed that portal vein invasion (p = 0.011) was an independent 
      predictor of worse clinical response. Portal vein invasion (p = 0.040), previous 
      cTACE treatment (p = 0.030), as well as abnormal serum creatinine level (BCr) 
      (p = 0.017) were independent factors that predicted worse ORR. In terms of 
      survival, higher Barcelona Clinic Liver Cancer (BCLC) stage (p = 0.029) predicted 
      for worse PFS, and abnormal albumin (ALB) (p = 0.011) and total serum bilirubin 
      (TBIL) (p = 0.009) predicted for worse OS. The number of patients with abnormal 
      albumin, total protein (TP), TBIL, alanine aminotransferase (ALT), and aspartate 
      aminotransferase (AST) were augmented at 1 week posttreatment and were similar at 
      1-3 months compared with baseline. The most common AEs were pain, fever, nausea, 
      and vomiting, and no severe AEs were observed in this study. DEB-TACE was 
      effective and tolerable in treating Chinese HCC patients, and portal vein 
      invasion, previous cTACE treatment, abnormal BCr, ALB, and TBIL appear to be 
      important factors that predict worse clinical outcome.
FAU - Sun, Junhui
AU  - Sun J
AD  - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of 
      Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of 
      Medicine, Zhejiang UniversityHangzhouP.R. China.
FAU - Zhou, Guanhui
AU  - Zhou G
AD  - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of 
      Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of 
      Medicine, Zhejiang UniversityHangzhouP.R. China.
FAU - Xie, Xiaoxi
AU  - Xie X
AD  - Interventional Center, Xinchang People's HospitalShaoxingP.R. China.
FAU - Gu, Wenjiang
AU  - Gu W
AD  - Department of Intervention, Jiaxing Second HospitalJiaxingP.R. China.
FAU - Huang, Jing
AU  - Huang J
AD  - Department of Hepatobiliary Surgery, Ningbo Medical Center, Lihuili Eastern 
      HospitalNingboP.R. China.
FAU - Zhu, Dedong
AU  - Zhu D
AD  - Department of Liver Oncology, Ningbo No. 2 HospitalNingboP.R. China.
FAU - Hu, Wenhao
AU  - Hu W
AD  - Department of Intervention, The First Affiliated Hospital of Wenzhou Medical 
      UniversityWenzhouP.R. China.
FAU - Hou, Qinming
AU  - Hou Q
AD  - Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's 
      HospitalHangzhouP.R. China.
FAU - Shi, Changsheng
AU  - Shi C
AD  - Department of Intervention, The Third Affiliated Hospital of Wenzhou Medical 
      UniversityRuianP.R. China.
FAU - Li, Tiefeng
AU  - Li T
AD  - Department of Radiology, Beilun District People's Hospital of NingboNingboP.R. 
      China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang UniversityHangzhouP.R. China.
FAU - Ji, Wenbin
AU  - Ji W
AD  - Department of Radiology, Taizhou Hospital of Zhejiang ProvinceLinhaiP.R. China.
FAU - Ying, Shihong
AU  - Ying S
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang UniversityHangzhouP.R. China.
FAU - Peng, Zhiyi
AU  - Peng Z
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang UniversityHangzhouP.R. China.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Radiology, Hangzhou Cancer HospitalHangzhouP.R. China.
FAU - Yu, Zhihai
AU  - Yu Z
AD  - Department of Vascular and Interventional Radiology, The Affiliated Hospital of 
      Medical College of Ningbo UniversityNingboP.R. China.
FAU - Ji, Jiansong
AU  - Ji J
AD  - Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang 
      University, The Fifth Affiliated Hospital of Wenzhou Medical UniversityLishuiP.R. 
      China.
FAU - Du, Haijun
AU  - Du H
AD  - Department of Intervention, Dong Yang People's HospitalDongyangP.R. China.
FAU - Guo, Xiaohua
AU  - Guo X
AD  - Department of Intervention, Jinhua Central HospitalJinhuaP.R. China.
FAU - Fang, Jian
AU  - Fang J
AD  - Department of Hepatobiliary Surgery, Quzhou People's HospitalQuzhouP.R. China.
FAU - Han, Jun
AU  - Han J
AD  - Department of Intervention, Jiaxing First HospitalJiaxingP.R. China.
FAU - Xu, Huanhai
AU  - Xu H
AD  - Division of Digestive Endoscopy, YueQing City People's HospitalYueqingP.R. China.
FAU - Sun, Zhichao
AU  - Sun Z
AD  - Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese 
      Medical UniversityHangzhouP.R. China.
FAU - Yu, Wenqiang
AU  - Yu W
AD  - Department of Intervention, Zhejiang Provincial People's HospitalHangzhouP.R. 
      China.
FAU - Shao, Guoliang
AU  - Shao G
AD  - Department of Intervention, Zhejiang Cancer HospitalHangzhouP.R. China.
FAU - Wu, Xia
AU  - Wu X
AD  - Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College 
      of MedicineHangzhouP.R. China.
FAU - Hu, Hongjie
AU  - Hu H
AD  - Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College 
      of MedicineHangzhouP.R. China.
FAU - Li, Ling
AU  - Li L
AD  - Department of Intervention, The First Affiliated Hospital of Wenzhou Medical 
      UniversityWenzhouP.R. China.
FAU - Zheng, Jiaping
AU  - Zheng J
AD  - Department of Intervention, Zhejiang Cancer HospitalHangzhouP.R. China.
FAU - Luo, Jun
AU  - Luo J
AD  - Department of Intervention, Zhejiang Cancer HospitalHangzhouP.R. China.
FAU - Chen, Yutang
AU  - Chen Y
AD  - Department of Intervention, Zhejiang Cancer HospitalHangzhouP.R. China.
FAU - Cao, Guohong
AU  - Cao G
AD  - Department of Radiology, Shulan (Hangzhou) Hospital, Zhejiang University 
      International HospitalHangzhouP.R. China.
FAU - Hu, Tingyang
AU  - Hu T
AD  - Department of Intervention, Zhejiang Provincial People's HospitalHangzhouP.R. 
      China.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190926
PL  - United States
TA  - Oncol Res
JT  - Oncology research
JID - 9208097
RN  - 0 (Antineoplastic Agents)
RN  - 3Z8479ZZ5X (Epirubicin)
RN  - 80168379AG (Doxorubicin)
RN  - AYI8EX34EU (Creatinine)
RN  - RFM9X3LJ49 (Bilirubin)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage
MH  - Bilirubin/blood
MH  - Carcinoma, Hepatocellular/mortality/*therapy
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - China
MH  - Creatinine/blood
MH  - Doxorubicin/*administration & dosage
MH  - Drug Delivery Systems
MH  - Epirubicin/administration & dosage
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/mortality/*therapy
MH  - Male
MH  - Microspheres
MH  - Middle Aged
MH  - Portal Vein/pathology
MH  - Progression-Free Survival
MH  - Prospective Studies
MH  - Serum Albumin, Human/analysis
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC7851504
COIS- The authors declare no conflicts of interest.
EDAT- 2019/09/29 06:00
MHDA- 2020/09/17 06:00
PMCR- 2020/02/07
CRDT- 2019/09/28 06:00
PHST- 2019/09/29 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2019/09/28 06:00 [entrez]
PHST- 2020/02/07 00:00 [pmc-release]
AID - OR1394 [pii]
AID - 10.3727/096504019X15662966719585 [doi]
PST - ppublish
SO  - Oncol Res. 2020 Feb 7;28(1):75-94. doi: 10.3727/096504019X15662966719585. Epub 
      2019 Sep 26.